Filing Flows

Filing Flows › Health Care › Intelligent Bio Solutions (INBS)

Intelligent Bio Solutions (INBS) earnings and revenue breakdown

Latest: Q4 FY26 · 10-K filed Aug 19, 2026 · Intelligent Bio Solutions (INBS) Q4 FY26 earnings results →

Q4 FY26 Revenue up 36% year over year to $1.1M · 342¢ of every $1 of revenue lost · operating margin -346.4%

Intelligent Bio Solutions made $1.1M in Q4 FY26 (+36% Y/Y): Sales of Goods - Cartidges $625K, Other sales - accessories $291K, Sales of Goods - Readers $229K. Operating margin -346.4%, net loss $3.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Aug 19, 2026.

Revenue$1.1M
Year over year+36%
Operating margin-346.4%
Net earnings−$3.9M
Operating cash flow−$3.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $1.1M in Q4 FY26, up 36% year over year and up 8% from the previous quarter. Sales of Goods - Cartidges was the largest line at 55% of revenue.

Gross margin was 46.8%, up 7.1 points from Q4 FY25. Operating costs exceeded revenue by $4.0M, an operating margin of -346.4%. Operating expenses grew 31% against revenue growth of 36%. The fastest-growing cost line was Other operating costs (+111%). The quarter ended with a net loss of $3.9M, wider than the previous quarter's $2.9M loss. Minority interests bore $10K of it: to shareholders the quarter was a loss of $3.9M.

Operating cash flow was −$3.2M. Non-cash charges added back $288K of depreciation and amortization and $97K of share-based compensation. Working capital and other items added $350K.

Quarterly history

Intelligent Bio Solutions revenue by quarterIntelligent Bio Solutions revenue by quarter$741KQ2 FY25$902KQ3 FY25$844KQ4 FY25$1.1MQ1 FY26$897KQ2 FY26$1.1MQ3 FY26$1.1MQ4 FY26
Intelligent Bio Solutions net earnings by quarterIntelligent Bio Solutions net earnings by quarter−$2.3MQ2 FY25−$2.6MQ3 FY25−$3.1MQ4 FY25−$3.0MQ1 FY26−$2.7MQ2 FY26−$2.9MQ3 FY26−$3.9MQ4 FY26
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q4 FY2610-KAug 19, 2026$1.1M+36%-346.4%−$3.9M−$3.2M
Q3 FY2610-QMay 13, 2026$1.1M+18%-277.8%−$2.9M−$4.3M
Q2 FY2610-QFeb 12, 2026$897K+21%-293.9%−$2.7M−$1.6M
Q1 FY2610-QNov 12, 2025$1.1M+11%-269.8%−$3.0M−$2.8M
Q4 FY2510-KAug 15, 2025$844K+16%-368.1%−$3.1M−$2.2M
Q3 FY2510-QMay 13, 2025$902K-0.6%-283.8%−$2.6M−$2.8M
Q2 FY2510-QFeb 13, 2025$741K-19%-305.5%−$2.3M−$2.3M

Charts

Intelligent Bio Solutions: revenue growth, year over year and quarter over quarterIntelligent Bio Solutions: revenue growth, year over year and quarter over quarterY/YQ/Q-19%Q2 FY25-1%+22%Q3 FY25+16%-6%Q4 FY25+11%+32%Q1 FY26+21%-19%Q2 FY26+18%+18%Q3 FY26+36%+8%Q4 FY26
Latest (Q4 FY26): Y/Y +36%, Q/Q +8%.
Intelligent Bio Solutions: where the cash came from (+) and went (−), FY26Intelligent Bio Solutions: where the cash came from (+) and went (−), FY26Other financing$15.0MOperating cash flow−$11.9MCash drawn (+) / kept (−)−$3.0MCapital spending−$126KAsset & business sales$40KExchange rates$1K
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Intelligent Bio Solutions: profit against cash, quarter by quarterIntelligent Bio Solutions: profit against cash, quarter by quarterNet incomeOperating cash flow−$2.7M−$2.4MQ1 FY25−$2.3M−$2.3MQ2 FY25−$2.6M−$2.8MQ3 FY25−$3.1M−$2.2MQ4 FY25−$3.0M−$2.8MQ1 FY26−$2.7M−$1.6MQ2 FY26−$2.9M−$4.3MQ3 FY26−$3.9M−$3.2MQ4 FY26
Latest (Q4 FY26): Net income −$3.9M, Operating cash flow −$3.2M.
Intelligent Bio Solutions: diluted shares by fiscal year (split-adjusted)Intelligent Bio Solutions: diluted shares by fiscal year (split-adjusted)625MFY2144MFY225MFY235MFY242MFY251MFY26
-99.8% since FY21: buybacks shrank the count; earlier years scaled for the 3-for-1 split before FY26, 20-for-1 split before FY24.
Intelligent Bio Solutions in its industry: growth against margin (111 companies, SIC 3841)Intelligent Bio Solutions in its industry: growth against margin (111 companies, SIC 3841)revenue growth, year over year →↑ operating marginmedian +10%median -9%MDLNMMMSYKBSXBDXBAXSOLVRMDDXCMWSTMMEDPODDGMEDTFXICUIMMSIIARTPENHAETNDMEMBCIRTCATECGKOSOFIXINSPNVCRUFPTATRCBVSAORTPRCTTCMDARAYANGOKIDSSKINLMATHTFLMDXGCERSSIBNTMCISTIMINFUBBNXKMTSOSURANIKDCTHRCELSGHTIRMDXTNTLUNGNPCEPDEXTELACARLLNSRSIMOBIAPYXSSIICVRXCLPTKRMDTLSIPROFSNWVCTSOIDXGUTMDRVPSNOAPREMNEPHDRIOVVOSBTCYNXGLMDAIMDNCPMINONE.SRTSSINTIVFNMTCNSPRAURXXAIRLUCDTNONRNXTVTAKUSAQICUVYCOHRGNCNSYPLSEPETVFEMYOSRHCODXOBIORDGLPAVMGUTSINBS (+36%, -100%)
Surgical & Medical Instruments & Apparatus; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Intelligent Bio Solutions

In this Annual Report on Form 10-K, unless the context otherwise requires, the terms “we,” “us,” “our,” “Company,” or “INBS” refer to Intelligent Bio Solutions Inc. together with its wholly owned subsidiaries. Intelligent Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December 5, 2016, under the laws of the state of Delaware. The Company’s Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales, Australia. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited (“IFP”), a company registered in England and Wales. Our headquarters are in New York City.

In its own words, from its 10-K, filed Aug 19, 2026.

Intelligent Bio Solutions against its Surgical & Medical Instruments & Apparatus peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +36% against the peers' median +5%. Operating margin: -346.4% against the peers' median 13.3%.

CompanyQuarterRevenueY/YOp. margin
INBS Intelligent Bio SolutionsQ4 FY26$1.1M+36%-346.4%
MDLN MedlineQ3 2026$7.9B+10%6.4%
MMM 3MQ3 2026$6.6B+1%23.7%
SYK StrykerQ3 2026$6.5B+8%15.9%
BSX Boston ScientificQ3 2026$5.1B+1%16.1%
BDX Becton DickinsonQ3 FY26$5.0B+5%13.3%
BAX Baxter InternationalQ3 2026$3.0B+5%7.6%
SOLV SolventumQ3 2026$1.9B-7%3.5%
RMD ResMedQ1 FY27$1.4B+6%32.0%

Source: Intelligent Bio Solutions 10-K on SEC EDGAR · CIK 1725430 · Surgical & Medical Instruments & Apparatus

13F: who owns INBS and who is buying

Largest holders of INBS (13F)Largest holders of INBS (13F)Armistice Capital, LLC$325KGeode Capital Management, LLC$48KStoneX Group$23KVanguard Capital Management LLC$13KUBS Group AG$13KVanguard Fiduciary Trust$9KTower Research Capital LLC$8KOsaic Holdings$460
Funds' net buying of INBS by quarter (13F)Funds' net buying of INBS by quarter (13F)$53K2025-12$645K2026-03−$973K2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on INBS

History

Every quarter: Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results · Q2 FY25 results

Compare INBS with

中文版：Intelligent Bio Solutions（INBS）财报

Español · Français